The role of angiotensin II in regulation of cerebrospinal fluid formation in rabbits.
The effect of central and peripheral administrations of angiotensin II (AII) on cerebrospinal fluid (CSF) formation was investigated in rabbits anesthetized with intravenous alpha-chloralose and urethane. CSF production was measured by the ventriculo-cisternal perfusion method with Blue dextran 2000 used as an indicator substance. AII infused intracerebroventricularly (i.c.v.) at rates of 5.5 and 55 pg min-1 significantly decreased CSF formation rate by 27% and 36%, respectively. This AII action could be completely blocked by simultaneously administered specific AII antagonist, [Sar1,Ala8]AII (saralasin), given i.c.v. at a rate of 5.5 ng min-1. Intracerebroventricular infusion of AII at a rate of 5.5 ng min-1 did not change CSF production. Saralasin, when given alone into the ventricular system (5.5 ng min-1), non-significantly increased CSF production by 12%. However, in 4 of the 6 animals studied, the rise in CSF production was statistically significant (by 23%). Intravenous infusion of AII at rates of 30 and 100 ng kg-1 min-1 was found not to change CSF formation rate. Also, i.c.v. administration of angiotensin I converting enzyme inhibitor, captopril (10 microliters min-1), did not influence CSF production. It is concluded that the centrally released AII can control CSF production. Our results suggest that under normal conditions, AII exerts a tonic inhibitory effect on CSF formation. In contrast, the blood-borne peptide seems not to influence this physiological process.
Chodobski
A
A
Department of Clinical and Applied Physiology, Institute of Physiological Sciences, School of Medicine, Warsaw, Poland.
Szmydynger-Chodobska
J
J
Segal
M B
MB
McPherson
I A
IA
D000804:Angiotensin II / Q000008:administration & dosage / Q000502:physiology*; D000818:Animals; D002552:Cerebral Ventricles; D002555:Cerebrospinal Fluid / Q000378:metabolism*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D005260:Female; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral; D008297:Male; D011817:Rabbits; D012504:Saralasin / Q000494:pharmacology
D002800:Cholinesterase Inhibitors; D000804:Angiotensin II; D012504:Saralasin